Evolus, Inc.
EOLS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for EOLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EOLS
Evolus, Inc. is a commercial-stage medical aesthetics company focused on developing and marketing products for the aesthetic market, including its Jeuveau® neurotoxin and a line of Evolysse® hyaluronic acid dermal fillers.
Key risk: High debt and negative equity
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 1 FDA decision for Evolus, Inc..
Evolus, Inc. is a commercial-stage medical aesthetics company focused on developing and marketing products for the aesthetic market, including its Jeuveau® neurotoxin and a line of Evolysse® hyaluronic acid dermal fillers.
- Total revenue of $84.1M for the six months ended June 30, 2026 [sec].
- Cash and equivalents of $45.2M as of June 30, 2026 [sec].
- Net loss of $8.1M for the six months ended June 30, 2026 [sec].
- Total debt of $156.7M as of June 30, 2026 [sec].
- Launched Evolysse® Form, Evolysse® Smooth, Evolysse® Sculpt, and Evolysse® Lips injectable HA gel products in Europe in May 2026 [sec_mda · as of 2026-08-05].
What works
- The company has a commercial-stage product portfolio with Jeuveau® and the newly launched Evolysse® line of dermal fillers in Europe, generating $84.1M in revenue for the first half of 2026 [sec].
- Management is actively pursuing U.S. regulatory approvals for Evolysse® Sculpt and Evolysse® Lips, which could expand its addressable market [sec_mda · as of 2026-08-05].
What to weigh
- The company has a significant debt burden of $156.7M in total debt and negative shareholders' equity of -$23.1M as of June 30, 2026 [sec].
- Evolus used $13.5M in cash for operating activities in the first half of 2026, and management notes it may need to raise additional capital to fund operations beyond the next twelve months [sec_mda · as of 2026-08-05].
- The company faces risks from potential tariffs on products imported from South Korea, which could impact its supply chain and costs [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
The company's financial position and liquidity are influenced by its outstanding indebtedness.
“Our financial position and liquidity are, and will continue to be, influenced by a variety of factors, including the level of our outstanding indebtedness and the related principal and interest we are obligated to pay on our indebtedness”
SEC MD&A · August 5, 2026
The company may need to raise additional capital to fund future operations.
“we may be required to raise additional capital to fund future operations through the incurrence of debt, the entry into licensing or collaboration agreements with partners, sale of equity securities, grants or other sources of financing”
SEC MD&A · August 5, 2026
The company launched its Evolysse product line in Europe in May 2026.
“supporting the growth of Evolysse ® Form, Evolysse ® Smooth, Evolysse ® Sculpt and Evolysse ® Lips injectable HA gel products in Europe following their launch in May 2026”
SEC MD&A · August 5, 2026
The company has material cash requirements from debt service and other obligations.
“As of June 30, 2026, our outstanding debt included $160.0 million of principal, due in 2029 and 2030, and approximately $53.0 million of estimated future interest payments, including $14.0 million due within the next twelve”
SEC MD&A · August 5, 2026
Risks & what to watch (4)›
Key risks
- High debt and negative equity — Total debt of $156.7M and negative shareholders' equity of -$23.1M as of June 30, 2026, indicating a leveraged balance sheet [sec].
- Need for additional financing — Management states it may need to raise capital beyond the next twelve months, with no assurance of availability on acceptable terms [sec_mda · as of 2026-08-05].
- Tariff exposure on imports — Potential tariffs on pharmaceutical products imported from South Korea could impact costs; company accelerated inventory imports in response [sec_mda · as of 2026-08-05].
- Operating cash burn — Used $13.5M in cash from operations in the first half of 2026, with expectations of continued significant expenses [sec_mda · as of 2026-08-05].
What to watch
- U.S. regulatory decisions for Evolysse® Sculpt and Evolysse® Lips [sec_mda · as of 2026-08-05].
- Ability to manage debt service obligations of $160M principal due in 2029 and 2030 [sec_mda · as of 2026-08-05].
- Impact of potential tariffs on imported products from South Korea [sec_mda · as of 2026-08-05].
- Revenue growth trajectory from the newly launched Evolysse® product line in Europe [sec_mda · as of 2026-08-05].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Evolus, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evolus, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
68.5 months
OCF -$4M · Net income -$8M
Lead: Approved
2 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
145
Total value held
$151.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,940,816 | $20.3M |
| blackrock, inc. | 4,290,383 | $17.6M |
| braidwell lp | 3,105,209 | $12.8M |
| perceptive advisors llc | 2,573,724 | $10.6M |
| millennium management llc | 1,461,159 | $6.0M |
| armistice capital, llc | 1,396,000 | $5.7M |
| geode capital management, llc | 1,381,338 | $5.7M |
| state street corp | 1,320,790 | $5.4M |
| rice hall james & associates, llc | 1,254,819 | $5.2M |
| pinnacle associates ltd | 1,158,895 | $4.8M |
Showing top 10 of 145 institutional holders of Evolus, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 10.2%
- Days to cover
- 9.0
- Shares short
- 6,656,973
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EOLS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Evolus, Inc.?
Evolus, Inc. is a commercial-stage medical aesthetics company focused on developing and marketing products for the aesthetic market, including its Jeuveau® neurotoxin and a line of Evolysse® hyaluronic acid dermal fillers.
What is Evolus, Inc.'s lead drug candidate?
Evolus, Inc.'s most advanced tracked candidate is evolysse (Preclinical) for Improvement of moderate to severe nasolabial folds facial wrinkles, mid face volume, lip fullness and infraorbital hollow correction..
Who is the CEO of Evolus, Inc.?
Mr. David Moatazedi is the chief executive officer of Evolus, Inc. (EOLS).
Where is Evolus, Inc. headquartered?
Evolus, Inc. (EOLS) is headquartered in Newport Beach, CA, United States.
What therapeutic areas does Evolus, Inc. focus on?
Evolus, Inc. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.